TY - JOUR
T1 - GEMMs Shine a Light on Resistance to Androgen Deprivation Therapy for Prostate Cancer
AU - Karantanos, Theodoros
AU - Thompson, Timothy C.
N1 - Funding Information:
The University of Texas MD Anderson Cancer Center is supported in part by the National Institutes of Health through Cancer Center Support grant CA16672.
PY - 2013/7/8
Y1 - 2013/7/8
N2 - Androgen deprivation therapy (ADT) for advanced prostate cancer inexorably leads to resistance, and clinically useful biomarkers are lacking. The value of genetically engineered mice for coclinical studies isclearly demonstrated in a recent publication that reveals XAF1, XIAP, and SRD5A1 as novel predictive biomarkers and therapeutic targets for ADT resistance.
AB - Androgen deprivation therapy (ADT) for advanced prostate cancer inexorably leads to resistance, and clinically useful biomarkers are lacking. The value of genetically engineered mice for coclinical studies isclearly demonstrated in a recent publication that reveals XAF1, XIAP, and SRD5A1 as novel predictive biomarkers and therapeutic targets for ADT resistance.
UR - http://www.scopus.com/inward/record.url?scp=84879997875&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879997875&partnerID=8YFLogxK
U2 - 10.1016/j.ccr.2013.06.007
DO - 10.1016/j.ccr.2013.06.007
M3 - Short survey
C2 - 23845440
AN - SCOPUS:84879997875
SN - 1535-6108
VL - 24
SP - 11
EP - 13
JO - Cancer cell
JF - Cancer cell
IS - 1
ER -